Growth factors play a part in every stage of the wound healing process that leads to scar tissue formation. Ocular scarring can cause decreased vision or blindness by virtue of the opaque nature of the new matrix that is deposited as scar tissue (as in the lens or cornea). In addition, the contractile nature of the ocular scar tissue is the most common cause of failed retinal attachment. Scar formation after glaucoma surgery can lead to surgery failure. Growth factors, particularly the transforming growth factor (TGF-βs), play a major role in scar tissue formation in the eye and induce the synthesis of growth factors that control cell migration, proliferation, enzyme production and matrix deposition. Neurotrophins are also neuroprotective and can delay ganglion cell death, thus delaying scar formation in the retina if retinal attachment is restored promptly. Growth factors can be seen as a major target for preventing ocular scarring in the future.
Deposition of fibrotic tissue and scarring can severely impair normal function of the cornea and clarity of vision (see Figure 1` ). Both the opaque nature of the scar tissue and corneal contraction hamper the focusing of light and, as such, affect the vision of patients.
The prevention of scarring is therefore crucial, and investigation of the implicating mechanisms can define the appropriate therapeutic strategies.
TGF-β isoforms, which are constantly expressed by the corneal epithelium, 22, 23 have been shown to regulate corneal epithelial, endothelial and fibroblast chemotaxis. 24 TGF-β is a key player in scar tissue formation 25, 26 in the corneal stroma. Ordinarily, the basement membrane of the stroma prevents the diffusion of molecules (such as TGF-β); however, following injury or surgery, this barrier becomes compromised, allowing for diffusion.
TGF-β signalling also contributes to the recruitment of bonemarrow-derived cells to the wound site, 27 which subsequently express fibronectin, one of the main ECM components of fibrous tissue. 28 In addition, TGF-β induces α-smooth muscle actin (α-SMA) expression by the stromal fibroblasts, which makes them more contractile and is a typical feature of fibrosis. 29, 30 Of the three isoforms, TGF-β2 has been suggested to play the most vital part in scar formation during corneal wound healing, and its specific inhibition has reduced fibrosis. 23 The TGF-βs act via the SMAD signalling pathways to onset α-SMA expression and actin stress fibres. 31 
Scarring of the Lens Capsule and the Role of Growth Factors
Cataract surgery is the most common eye operation worldwide. The most common complication is posterior capsule opacification (PCO), which can occur in to 20-40% of patients undergoing surgery 34,35 (see Figure 2 ). As with other fibrotic disorders, TGF-β is highly implicated in PCO development.
The lens is an invagination of the surface ectoderm that is formed during embryogenesis.
38-40 Loss of vision attributed to scar formation in the lens has been attributed to TGF-βs. 19, 20 As with other tissues, TGF-β upregulates the expression of α-SMA, promoting the epithelialto-myofibroblast transition of lens epithelial cells (LECs). Multiple TGF-β is known to be present within aqueous humour, 43 but is largely inactive as it is secreted bound to the propeptide latency-associated protein (LAP). 44, 45 Annes et al. 45 suggested that the TGF-β-LAP complex, active TGF-β and TGF-β-binding protein have separate roles in wound repair. 45 The latent TGF-βs, for example, are defined as 'detectors' that detect changes in the ECM or inflammation. When these ECM changes occur, the latent TGF-β form becomes activated.
Following cataract surgery, TGF-β levels in the eye rise, 27,28 decreasing rapidly a few days after the surgery. 46 Wormstone et al. demonstrated that contraction of a capsular (lens) bag after exposure to TGF-β2 for just two days was no different from that of a capsular lens bag exposed to TGF-β2 for the full 28 days. 47 These data suggest that TGF-β initiated a cascade of events (presumably involving CTGF) leading to LEC transdifferentiation and scar formation.
As a target for pharmaceutical intervention, antibodies to TGF-β2 may be useful in the prevention of fibrosis and the downstream activation of CTGF. 29, 31 While monoclonal antibodies were successful in both in vitro and ex vivo PCO models, a rodent model of PCO failed to show any significant beneficial effect of the blocking antibody. 48 Unlike FGF, EGF cannot overcome TGF-β-induced cell apoptosis. 49 It is believed to promote the proliferation of cells in an in vitro posterior bag explant. 53 The effect of EGF can be inhibited by blocking EGF receptors using a receptor antagonist. HGF has also been shown to induce LEC proliferation; this effect can be blocked using a neutralising antibody against the HGF receptor. 54 The Influence of Growth Factors on Post-glaucoma Filtration Surgery Scarring
Glaucoma filtration surgery (GFS) is aimed at reducing the intraocular pressure (IOP) in patients that are non-responsive to conventional therapies for reducing elevated levels of IOP. The main cause of GFS failure is the conjunctival scarring response (see Figure 3) . 55 The use of mitomicin C (MMC) and 5-fluorouracil (5-FU) to prevent scarring has improved surgical outcomes following GFS. 56 Unfortunately, these agents are associated with many potentially blinding side effects. 57 The site of the wound healing response in GFS has been shown to contain a large number of growth factors. 58 Much work has been undertaken to study how the modulation of these growth factors may influence the response of conjunctival fibroblasts and allow for more effective control of GFS scarring.
TGF-β is the key stimulatory growth factor in the aqueous fluid. 59 As with other ocular tissues, TGF-β controls wound healing by stimulating fibroblasts to deposit ECM, promoting cellular proliferation and inducing the expression of MMPs. 59, 60 In a clinically validated in vivo model of GFS, a monoclonal antibody against TGF-β2 improved the surgical outcome with minimal destruction of local tissue. 61 Unfortunately, subsequent human clinical trials did not show a similar significant effect. 62 As with the rodent model of PCO, 66 the failure of this clinical trial was attributed to the local ocular bioavailability of the antibodies, making it extremely difficult to obtain therapeutic antibody levels at the site of wound healing.
63
Other promising therapeutic strategies targeting TGF-β in experimental GFS models include Tranilast ((N-(3u,4u)-dimethoxycinnamoyl)
anthranilic acid) and suramin. 64 Gene silencing has also shown promise for preventing GFS scarring, where short interfering RNA (siRNA) was The potential involvement of p38MAPK via its effects on CTGF and of the monocyte chemoattractant protein (MCP-1) has been studied. 66 Therefore, the inhibition of p38MAPK has also been proposed as a possible future therapeutic option. The effect of the epiretinal membrane (EM) formation is dependent on the site of scarring. EM formation proximal to or at the site of the macular can lead to vision loss and visual distortion and monocular dipilopia (see Figure 4) . 70 The migration and proliferation of many cell types, including RPE, fibroblasts and Müller glia, have been attributed to PVR development; 33,69-72 RPE cells are believed to dedifferentiate and adopt a fibroblastic phenotype during PVR development. 71 Where RPE migration is concerned, a tear in the retina or rhegmatogenous detachment allows growth-factor-and cytokine- . 79 In addition, retinal membranes from PVR patients have been
shown to have elevated levels of those MMPs. 80 The vitreous of patients with PVR has been shown to be high in both MMP-2 and MMP-9. 4 Neutralisation of a combination of MMPs using antibodies was shown to be required to inhibit RPE-mediated gel contraction; individual MMP antibodies were not effective. 71 A broadspectrum MMP inhibitor (ilomastat) was shown to inhibit collagen gel contraction by RPEs more effectively than the combined antibodies.
The effects of ilomastat were shown to be reversible after replacement of the media, suggesting effective, reversible inhibition of contraction. MMPs are, as such, a valuable target for PVR development. It may be feasible to inhibit both the proliferation of RPE and MMP activity using a combination of a broad-spectrum MMP inhibitor plus an anti-inflammatory. 71 Aside from the importance of cytokines such as TNF-α, which is believed to control intergrin expression and promote migration of RPE, 77 growth factors play an important role in the formation of PVR.
It has been suggested that HGF is important in the early stages of PVR development. 81 This was realised based on the strong cellular staining of HGF on PVR specimens and relatively weak staining on scar tissue. Hinton et al. suggested that HGF, which acts mainly on epithelial cells, promotes cell division and migration of RPE in PVR. It has been hinted that HGF acts via an autocrine system in RPEs as they express both HGF and its receptors. 82 HGF is suggested to promote the breakdown of RPE tight junctions, 83 possibly as a result of downregulation of zona occuldens 1 (zo-1, a tight junction protein that is involved in cell-cell signalling).
TGF-β probably plays the most important role in the scaring response of the retina. Of the three TGF-βs expressed in mammals, TGF-β2 is the most important isoform for retinal scarring; indeed, a significant correlation exists between the levels of TGF-β2 expression and the severity of retinal scarring. 84 TGF-β2 mediates RPE production of collagen I and fibronectin, 85, 86 and promotes cell migration 86 and the transition of RPE into the fibroblastic phenotype. 87 CTGF again and that has now been widely adopted around the world. They also carried out the first trial in the world to show a significant reduction in retinal scarring. They have won several awards, including the first international ARVO Pfizer Translational Medicine.
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